ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$263.78
−0.09%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$263.29
From 52W high−0.82%
Volume7.98M
Market cap$466.13B
P/E (TTM)74.3x
P/S (TTM)7.2x
Div yield2.59%
Key dataSep 18, 2026
Open
$263.29
From 52W high
−0.82%
Volume
7.98M
Market cap
$466.13B
ValuationView details →
P/E (Fwd)
17.4x
EV/EBITDA
25.0x
P/E (TTM)
74.3x
RSI (14)
58.6
MomentumView details →
1D Return
−0.09%
YTD Return
+15.43%
SummaryUpdated Jun 1, 2026
AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company that was spun off from Abbott Laboratories in 2013. The company emerged as an independent entity to focus exclusively on research-based pharmaceuticals, inheriting Abbott's established drug portfolio including the blockbuster immunology drug Humira. Since its inception, AbbVie has evolved from a company heavily dependent on a single product to a diversified pharmaceutical enterprise with a robust pipeline across multiple therapeutic areas. Today, AbbVie operates as one of the world's largest biopharmaceutical companies, with operations spanning immunology, oncology, neuroscience, and aesthetics.
Similar companies
Latest newsMore news →
AbbVie presented new real-world data supporting the effectiveness of VRAYLAR (cariprazine) in adults with major depressive disorder and bipolar I depression at Psych Congress 2026 in New Orleans.2d agoCrohn's and Colitis Canada and AbbVie Canada announced the 2026 recipients of the AbbVie IBD Scholarship Program, awarding fifteen students across Canada $5,000 each.3d ago